Cargando…

Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination

INTRODUCTION: The leading professional organizations in the field of hematology have recommended severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) vaccination for all patients with hematologic malignancies notwithstanding efficacy concerns. Here we report a systematic literature review re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guven, Deniz C, Sahin, Taha K, Akın, Serkan, Uckun, Fatih M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Brief Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982368/ https://www.ncbi.nlm.nih.gov/pubmed/35274729 http://dx.doi.org/10.1093/oncolo/oyac032

Ejemplares similares

SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research
por: Guven, Deniz C, et al.
Publicado: (2022)

Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination
por: Sriwijitalai, Won, et al.
Publicado: (2022)

Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review
por: Guven, Deniz C., et al.
Publicado: (2021)

SARS-CoV-2 antibody seroconversion in care home
por: Shang, Joan, et al.
Publicado: (2020)

Seroconversion to mRNA SARS-CoV-2 Vaccines in Hematologic Patients
por: Fattizzo, Bruno, et al.
Publicado: (2022)

Seroconversion Following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients
por: Spencer, Elizabeth A, et al.
Publicado: (2021)

Factors Associated with Seroconversion after COVID-19 Vaccination in Patients with Hematologic Malignancies
por: Ollila, Thomas A., et al.
Publicado: (2021)

Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies
por: Greenberger, Lee M., et al.
Publicado: (2022)

SARS-CoV-2 vaccination improves HBV seroconversion rate through heterological immunity
por: Anft, Moritz, et al.
Publicado: (2023)

Healthcare worker seroconversion for SARS-CoV-2 at two large health systems in San Diego
por: Nicholson, Laura, et al.
Publicado: (2021)

Data-Driven identification of chemopreventive agents for breast cancer
por: GÜVEN, Deniz Can, et al.
Publicado: (2020)

Characteristics of patients with hematologic malignancies without seroconversion post-COVID-19 third vaccine dosing
por: Hallmeyer, Sigrun, et al.
Publicado: (2023)

SARS-CoV-2 vaccines in patients with SLE
por: Tang, Wei, et al.
Publicado: (2021)

RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies
por: Bigenwald, Camille, et al.
Publicado: (2023)

Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine
por: Belda, Francisco, et al.
Publicado: (2022)

Cycle threshold predicted mortality in a cohort of patients with hematologic malignancies infected with SARS-CoV-2
por: Santarelli, Ignacio Martín, et al.
Publicado: (2023)

Seroconversion after Inactive SARS-CoV-2 Vaccination and Obesity: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Self-prescribed Ivermectin use is associated with a lower rate of seroconversion in health care workers diagnosed with COVID, in a dose-dependent response
por: Pedroso, Célia, et al.
Publicado: (2021)

High Rates of Seroprotection and Seroconversion to Vaccine-Preventable Infections in the Early Post–Autologous Stem Cell Transplant Period
por: Hall, Victoria G, et al.
Publicado: (2023)

SARS-Cov-2 Infection and Seroconversion Rates in Healthcare Providers Prior to COVID-19 Vaccine Rollout
por: Shin, Sanghyuk S., et al.
Publicado: (2023)

Assessment of Seroconversion after SARS-CoV-2 Vaccination in Patients with Lung Cancer
por: Trontzas, Ioannis P., et al.
Publicado: (2022)

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
por: Malard, Florent, et al.
Publicado: (2021)

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
por: Greenberger, Lee M., et al.
Publicado: (2021)

SARS-CoV-2 seroconversions and chains of infection in healthcare professionals in a German maximum care provider (The CoSHeP study)
por: van Bremen, Kathrin, et al.
Publicado: (2021)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in inadvertently vaccinated healthy children
por: Fernandes, Eder Gatti, et al.
Publicado: (2021)

Immunogenicity of candidate SARS-CoV-2 DNA vaccines based on the spike protein
por: Lim, Heeji, et al.
Publicado: (2022)

Vaccines against SARS‐CoV‐2 are safe to administer in patients with antibodies to pegaspargase
por: Swanson, Hope D., et al.
Publicado: (2022)

Comparison of Plasma Concentrations of Posaconazole with the Oral Suspension and Tablet in Korean Patients with Hematologic Malignancies
por: Suh, Hyeon Jeong, et al.
Publicado: (2017)

Can vitamin D status influence seroconversion to SARS-COV2 vaccines?
por: Shahini, Endrit, et al.
Publicado: (2022)

Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients
por: Patelli, Giorgio, et al.
Publicado: (2022)

Inactivated vaccine for SARS-CoV-2
por: Risson, Emma
Publicado: (2020)

A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern
por: Brinkkemper, Mitch, et al.
Publicado: (2021)

Modeling comparative cost-effectiveness of SARS-CoV-2 vaccine dose fractionation in India
por: Du, Zhanwei, et al.
Publicado: (2022)

Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies
por: Mohan, Meera, et al.
Publicado: (2022)

Infection‐induced seroconversion and seroprevalence of SARS‐CoV‐2 among a cohort of children and youth in Montreal, Canada
por: Zinszer, Kate, et al.
Publicado: (2023)

Evaluation of SARS-CoV-2 Serological Testing in Patients with Multiple Myeloma and Other Hematologic Malignancies on Monoclonal Antibody Therapies
por: Mahimainathan, Lenin, et al.
Publicado: (2020)

Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies
por: Zhong, Chaojie, et al.
Publicado: (2021)

PF-D-Trimer, a protective SARS-CoV-2 subunit vaccine: immunogenicity and application
por: Zhang, Zhihao, et al.
Publicado: (2023)

Seroprevalence of Hepatitis A Virus in Pediatric Patients with Hematologic Malignancies after Chemotherapy and Hematopoietic Cell Transplantation
por: Moon, Ja Un, et al.
Publicado: (2019)

Holistic Analysis of Coronavirus Literature: A Scientometric Study of the Global Publications Relevant to SARS-CoV-2 (COVID-19), MERS-CoV (MERS) and SARS-CoV (SARS)
por: Şenel, Engin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nptou32a8hlih5cl41j89a2br5